Improving Bone Health by Optimizing the Anabolic Action of Wnt Inhibitor Multitargeting
Improving Bone Health by Optimizing the Anabolic Action of Wnt Inhibitor Multitargeting
About this item
Full title
Author / Creator
Publisher
Hoboken, USA: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Hoboken, USA: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
ABSTRACT
Sclerostin antibody (romosozumab) was recently approved for clinical use in the United States to treat osteoporosis. We and others have explored Wnt‐based combination therapy to disproportionately improve the anabolic effects of sclerostin inhibition, including cotreatment with sclerostin antibody (Scl‐mAb) and Dkk1 antibody (Dkk1‐mAb)....
Alternative Titles
Full title
Improving Bone Health by Optimizing the Anabolic Action of Wnt Inhibitor Multitargeting
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_8bf70de22fa94fbbae843dd1f34ce38c
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8bf70de22fa94fbbae843dd1f34ce38c
Other Identifiers
ISSN
2473-4039
E-ISSN
2473-4039
DOI
10.1002/jbm4.10462
